Partnership Potential FYR Bio has active collaborations with Mayo Clinic for Parkinson's biomarker discovery and with Medicover for North American diagnostic development. This established ecosystem signals credibility and a ready pathway for co-development of EV-based biomarkers, companion diagnostics, and trial-enrichment services. Sales opportunities include offering the EVO platform as a CRO/partner solution to pharma and diagnostics companies and expanding co-development deals in oncology and neuroscience.

AI Driven EVO FYR's EVO platform enriches extracellular vesicles from diseased cells and delivers AI-enabled multiomic insights from a simple blood draw. This enables faster biomarker discovery, patient stratification, and real-time monitoring in trials. For sales teams, position EVO as a high-value service or licenseable technology to accelerate biomarker pipelines and companion diagnostic programs for pharma and biotech customers.

Expansion Investment FYR has announced funding for expansion in oncology and neuroscience and is building scale to support larger programs, including a COO appointment in 2026. This momentum creates an opening to pursue enterprise agreements for end-to-end biomarker discovery, diagnostic development, and trial-support services with pharma, biotech, and academic partners focusing on cancer and neurological diseases.

Leadership Momentum Barbara Zehentner's appointment as COO signals a renewed focus on operations, manufacturing readiness, and delivery for large-scale collaborations. The leadership addition improves credibility with enterprise customers, reduces program risk, and supports longer, multi-phase engagements in target indications.

Compliance Advantage FYR's technology stack aligns with HIPAA and regulated healthcare requirements, reinforcing data privacy and security prerequisites for pharma and diagnostics partners. This compliance posture lowers friction in pilot programs and scale deployments, enabling faster go-to-market for biomarker discovery and diagnostic services.